Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Pump's daily trading recs, emphasis on short selling -- Ignore unavailable to you. Want to Upgrade?

To: Art Baeckel who wrote (5752)	10/5/2001 1:31:28 PM
From: Art Baeckel	Read Replies (1) \| Respond to of 6873

Lifecore Receives FDA Center Director's Determination to Approve GYNECARE INTERGEL Adhesion Prevention Solution PMA CHASKA, Minn., Oct 5, 2001 (BUSINESS WIRE) -- LIFECORE BIOMEDICAL, INC. (Nasdaq: LCBM chart, msgs) announced today that it has received notice that Dr. David W. Feigal, Director, FDA's Center for Devices and Radiological Health, has concurred with the unanimous recommendation for approval of Lifecore's adhesion prevention product PMA made by the FDA's Medical Devices Dispute Resolution Panel ("MDDRP") on September 6, 2001. Under FDA guidelines, Dr. Feigal evaluated the MDDRP's Statement of Findings and recommendations prior to making his determination that the PMA should be approved. The current action is Dr. Feigal's concurrence with the MDDRP's conclusion that Lifecore's scientific data successfully demonstrated that GYNECARE INTERGEL Adhesion Prevention Solution is a safe and effective surgical adjuvant for reducing the incidence, extent, and severity of post-surgical adhesions after gynecological surgery. After finalization of the labeling and the summary of safety and effectiveness, the Company will be approved to market GYNECARE INTERGEL Adhesion Prevention Solution in the US. Lifecore President and CEO, Jim Bracke, commented "We are very pleased with the speed of the Director's response and the completion of this chapter in the research and development of this product. We are in the process of working with FDA to complete product labeling. As soon as we complete this final FDA administrative action, we can begin working to change surgery." GYNECARE INTERGEL Adhesion Prevention Solution has been in research and development status since 1989. The initial pivotal human clinical trial, which was the source of the scientific dispute that led to the MDDRP, began in March 1996. The PMA application which included that clinical trial data was filed with the FDA in March 1999 and formally accepted for expedited review in May 1999. The product has been marketed outside the US in selected countries since 1998 by Lifecore's global marketing partner, GYNECARE, the women's healthcare division of ETHICON, INC., a Johnson & Johnson Company. Lifecore estimates that GYNECARE will begin US marketing in early 2002. Certain statements in this release are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Statements implying timing or outcome of the marketing success of the adhesion prevention product or future product development success are subject to change. Because of numerous risks and uncertainties in the complex regulatory aspects of Lifecore's business activity, actual results may differ materially from those implied. Investors are strongly cautioned to review more detailed discussions of those risks presented in the Company's reports on Forms 10-Q and 10-K. Lifecore Biomedical manufactures biomaterials and medical devices for use in various surgical markets and provides specialized contract aseptic manufacturing services. Additional general corporate information is available on the Internet at through its website at lifecore.com and by electronic mail at info@Lifecore.com. GYNECARE INTERGEL, GYNECARE, and ETHICON, INC. are registered trademarks of ETHICON, INC., a Johnson & Johnson Company. Contact: Lifecore Biomedical Inc., Chaska James W. Bracke, 952/368-4300 or Dennis J. Allingham, 952/368-4300 or Colleen M. Olson, 952/368-4300 ART